MIRENA SUMMARY
MIRENA ® (levonorgestrel-releasing intrauterine system) consists of a T-shaped polyethylene frame (T-body) with a steroid reservoir (hormone elastomer core) around the vertical stem. The reservoir consists of a cylinder, made of a mixture of levonorgestrel and silicone (polydimethylsiloxane), containing a total of 52 mg levonorgestrel. The reservoir is covered by a silicone (polydimethylsiloxane) membrane. The T-body is 32 mm in both the horizontal and vertical directions. The polyethylene of the T-body is compounded with barium sulfate, which makes it radiopaque. A monofilament brown polyethylene removal thread is attached to a loop at the end of the vertical stem of the T-body.
MIRENA ® is indicated for intrauterine contraception for up to 5 years. Thereafter, if continued contraception is desired, the system should be replaced.
|
NEWS HIGHLIGHTSMedia Articles Related to Mirena (Levonorgestrel)
US funding revamps African contraceptive drive (AFP)
Source: Y! Health News Search RSS Feed [2009.11.18]
AFP - A new 12 million dollar family planning drive launched here Wednesday highlights how Obama administration funding has revamped a contraception drive in Africa and developing states, UN officials said, noting a sharp turnaround from the Bush era.
Terrence Higgins Trust Welcomes Department Of Health Nursing Degree Announcement, UK
Source: HIV / AIDS News From Medical News Today [2009.11.15]
HIV and sexual health charity Terrence Higgins Trust has welcomed the announcement by the Department of Health that all new nurses will be educated to degree level from 2013. Terrence Higgins Trust (THT) currently employs nurses who work in Chlamydia screening programmes for young people, HIV testing clinics and clinics that offer contraception services and screening for sexually transmitted infections.
Published Studies Related to Mirena (Levonorgestrel)
Prevention of tamoxifen induced endometrial polyps using a levonorgestrel releasing intrauterine system long-term follow-up of a randomised control trial. [2009.09]
OBJECTIVES: In a RCT, we have previously shown that the levonorgestrel intrauterine system (LNG-IUS, Mirena) produces a decidual response protecting the endometrium at one year follow-up. We here report on the long-term follow-up of this group of women, to test the hypothesis that a LNG-IUS could prevent the pro-proliferative uterine responses of tamoxifen for up to 4.5 years... CONCLUSION: This study confirms that LNG-IUS induces benign endometrial changes and prevents endometrial polyps but only during its use in women taking tamoxifen. Endometrial thickness is a risk factor for the development of polyps.
The effect of levonorgestrel-releasing intrauterine device on menorrhagia in women taking anticoagulant medication after cardiac valve replacement. [2009.08]
BACKGROUND: This study was conducted to evaluate the effect of levonorgestrel-releasing intrauterine devices (LNG-IUDs) on menorrhagia in patients receiving anticoagulant therapy after cardiac valve replacement... CONCLUSION: LNG-IUDs can be considered as an effective non-surgical treatment for menorrhagia in women receiving anticoagulant therapy after cardiac valve replacement.
Effects of doxycycline on serum and endometrial levels of MMP-2, MMP-9 and TIMP-1 in women using a levonorgestrel-releasing subcutaneous implant. [2009.06]
BACKGROUND: Endometrial spotting and/or bleeding (ESB) occurs in levonorgestrel subcutaneous implant (LNG SI) users. Matrix metalloproteinases (MMPs) may play a role in ESB... CONCLUSION: LNG SI increased serum MMP-9 and TIMP-1 levels, while DOX decreased both serum and endometrial MMP-9 levels.
A Canadian, multicentre study comparing the efficacy of a levonorgestrel-releasing intrauterine system to an oral contraceptive in women with idiopathic menorrhagia. [2009.04]
OBJECTIVES: To evaluate the efficacy of a levonorgestrel-releasing intrauterine system (LNG-IUS) compared with a combined oral contraceptive containing 1 mg norethindrone acetate and 20 mg ethinyl estradiol (OC1/20) in reducing menstrual blood loss (MBL) in women with idiopathic menorrhagia... CONCLUSION: Both the LNG-IUS and the combined oral contraceptive effectively decreased menstrual blood loss in women with idiopathic menorrhagia. The overall clinical benefit was more pronounced with LNG-IUS than with OC1/20.
Uterine ultrasonographic changes during endometriosis treatment: a comparison between levonorgestrel-releasing intrauterine devices and a gonadotropin-releasing hormone agonist. [2008.12]
We compared the effects of levonorgestrel-releasing intrauterine devices (LNG-IUD) and a gonadotropin-releasing hormone agonist (GnRHa) on uterine volume, uterine arteries pulsatility index (PI) and endometrial thickness before and after six months of endometriosis treatment...
Clinical Trials Related to Mirena (Levonorgestrel)
Mirena Efficiency and Tolerability During the First Year of Use [Completed]
In this trial the efficacy and safety of Mirena was investigated during the first year of
use
Postplacental or Delayed Insertion of the Levonorgestrel-IUD After Vaginal Delivery [Active, not recruiting]
This study is a randomized controlled trial comparing 6 month usage rates of the
levonorgestrel-releasing intrauterine device (LNG-IUD) when inserted postplacentally after
vaginal delivery or delayed placement at 6-8 weeks postpartum. Given the high rate of
unintended pregnancy in the United States, particularly in postpartum women, there is a need
for reliable, effective, long-term contraception such as the IUD in postpartum women.
Postplacental insertion of intrauterine contraception would help to address this need. The
primary hypothesis of this study is that use of the LNG-IUD at 6 months after vaginal
delivery will be higher in women who have immediate postplacental insertion as compared to
delayed insertion 6-8 weeks following delivery.
Advance Supply of Emergency Contraception Compared to Routine Postpartum Care in Teens [Active, not recruiting]
This is a pilot randomized controlled trial to asses the effects of advanced supply of
emergency contraception versus routine care in a teen postpartum population. The goals are
to assess feasibility of recruiting and retaining postpartum teens; to obtain estimates of
the prevalence of (use of Plan B, primary contraceptive continuation, unprotected intercourse
exposure, and pregnancy rates), in postpartum teens given advanced supply of Plan B; to
assess whether or not (lack of use of Plan B, contraceptive method non-continuation, and
unprotected intercourse exposure), are surrogate markers for risk of unintended pregnancy.
Bleeding Pattern and User Satisfaction During Second Consecutive MIRENA® in Contraception and Treatment of Menorrhagia [Active, not recruiting]
Mirena Observational Program [Recruiting]
Mirena is used for long-term in Kazakhstan, and in our observational program we would like
to study patients distribution per indications of Mirena, and also patient compliance within
a year after Mirena insertion.
For patients with all approved indications for Mirena use: contraception, treatment of
menorrhagia and protection from endometrial hyperplasia during estrogen replacement therapy
|
